Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis

Figure 2

Forest plots of comparison in Group A (PD-1 or PD-L1 versus Chemotherapy). (a) The OR of rash for all grades calculated by the random effect (RE) model: subgroup analyses were performed according to the types of immune checkpoint inhibitors (PD-1 or PD-L1). (b) The OR of rash for all grades calculated by the random effect (RE) model: subgroup analyses were performed according to the treatment lines (first or second line). (c) The OR of rash for all grades calculated by the random effect (RE) model: subgroup analyses were performed based on drug name, tumor type, and immune checkpoint type. (d) The OR of rash for all grades calculated by the random effect (RE) model: subgroup analyses were performed based on drug name, tumor type, immune checkpoint type, and I2 value.

(a)

(b)

(c)

(d)